Where Single-Use Fermenters Fit in Biologics Manufacturing
Whitepaper
Published: September 23, 2026
Brought to you by
Agilent Advanced Therapeutics
Credit: iStock.
Producing biologics through development, clinical studies, and commercialization calls for different fermentation scales and production needs. Single-use fermenters can support smaller-scale development and clinical production, while stainless steel systems remain suited to larger-volume manufacturing.
This whitepaper examines how single-use and stainless steel fermentation can work together across a clinical-to-commercial program, covering their applications, operational differences, and limitations.
Download this whitepaper to explore how:
- Single-use fermenters can produce proteins, pDNA, enzymes, Fabs, and other products made through microbial fermentation
- Faster changeovers and elimination of cleaning/sterilization steps reduce downtime and increase facility utilization
- Companies can transition from single-use to stainless steel systems as production scales from early clinical studies toward commercialization
White Paper
Large-scale, single-use fermentation technology using aerobic
microbial expression systems offers an excellent complement
to stainless steel bioreactors for clinical-to-commercial scale
production of recombinant proteins.
Introduction
For decades, microbial fermentation has been used for the commercialization of
biologics, with the efficient fermentation of such recombinant proteins as insulin
in stainless steel (SS) bioreactors as large as 100,000 L. The biopharmaceutical
industry is now at a pivotal stage due to the development and clinical success of
a diverse range of new modalities—RNA therapeutics, plasmid DNA (pDNA), and
mRNA vaccines, cell and gene therapy, and antibody fragments—that are being used
for indications such as oncology, multiple sclerosis, and autoimmune disorders.
While SS equipment continues to be vital for commercial manufacturing of many
biologics, it comes with high up-front costs and the ongoing expense in time and
labor required to operate it. This works well when a company is producing large
amounts of drug substance but has limitations for the smaller volumes needed
during development and clinical studies. The early stages of a drug clinical
development program need processes that increase speed to market. What has
been missing is a fast, cost-effective solution for fermentation studies that can be
used during development and clinical-phase manufacturing.
Recent innovations in single-use fermenters (SUFs) mean that startups and large
biopharmaceutical companies alike can now produce biologics for tech-transfer
scale-up of recombinant proteins for phase 1 or early-phase 2 clinical trials, and even
to treat orphan or rare indications. These closed, sterile SUFs—100 L and large-scale
1,000 L—are designed to provide mixing, oxygen transfer, and cooling capabilities
comparable to SS bioreactors while being more agile and avoiding the high fixed
costs of stainless steel.
Single-Use Fermenters for the
Production of Biologics
2
A valuable niche exists to manufacture personalized medicines, for which multiple discrete batches are required, and single-use equipment would have a huge advantage over SS with respect to batch segregation and cross‑contamination risks.
Companies that want to start a clinical program and take it all the way to commercial launch are no longer faced with an either/or choice of single-use versus SS bioreactors. The combination of the two can be ideal for those engaged in clinical-to-commercial scale production. They would begin with SUFs for production of biologics needed for development, early-phase clinical trials, and orphan indications. Then, for large-scale production of successful drug products—mRNA vaccines or blockbuster biologics— manufacturers can transition to larger SS bioreactors (for example, >1,000 L up to 17,000 L, or larger) to manufacture enough product for phase 3 clinical trials and commercialization.
SUFs have overcome the challenges that existed in the early days, when single-use cell culture systems for microbial fermentation were simply repurposed from bioreactors designed for mammalian cell culture. Early versions demonstrated poor oxygen transfer, limited mixing, and insufficient temperature control. With engineering and design innovations, SUFs are now able to complement SS fermenters.
The addition of SUFs improves process flexibility, leads to faster turnaround times, enhances quality, reduces regulatory burden, and lowers costs by enabling better use of facility capacity.
The addition of SUFs improves process flexibility, leads to faster turnaround times, enhances quality, reduces regulatory burden, and lowers costs by enabling better use of facility capacity. In this white paper we will discuss these benefits of SUFs and how they fit into a clinical-to-commercial scale program.
SUFs can grow with a clinical-to-commercialization program
Single-use fermentation technology is similar in many ways to conventional stainless-steel systems. The main difference is that SUFs use disposable sterile plastic bags that don't require the traditional high‑intensity preparation for cleaning, sterilization, and decontamination of SS bioreactors, which are expensive and time‑consuming processes.
SUFs come in various sizes, including 10 to 30 L process development fermenters, 100 L seed fermenters, and the industry-leading 1,000 L fermenter from ABEC. They can be used for all drug substances expressed in microbial cells, including pDNA, proteins, enzymes, Fabs, and bioconjugates. High-intensity mixing of microbial cultures, which optimizes oxygen transfer, is possible because of the generally low sensitivity of these cells to shearing. Mixing the cells within the SUF can be achieved by using various different impeller styles and designs to ensure an optimal oxygen transfer rate (OTR).
A complete biologics program, from development and clinical studies to commercialization, can include smaller process development bioreactors, SUFs for clinical studies drug production (in 100 L and 1,000 L fermenters), and SS for large-scale cGMP production of commercial drug products (in 100 L, 3,000 L, and up to 17,000 L fermenters).
What is microbial fermentation?
Microbial fermentation is the process of growing bacterial or yeast cells in liquid culture so the cells can express a drug substance, usually a recombinant protein such as insulin, human growth hormone, cytokines, monoclonal antibodies
(mAbs), or antibody fragments (Fabs). When compared to mammalian cell culture, microbial fermentation has the benefits of less complex genetic engineering, simpler growth media, faster cell growth, and a much shorter production time. The main microbes used are the bacterium, E. coli, and the yeasts, S. cerevisiae, and Pichia pastoris.
Quicker changeovers between batches
Perhaps the main benefit of SUFs is the rapid changeovers that are possible with disposable equipment. SS systems can be costly for a number of reasons—most notably, the costs of fixed equipment and labor—but the cleaning time between successive batches may be the most significant cost differential when compared to SUFs. Changeovers of SS systems can take several weeks causing downtime that results in significant loss of throughput. In contrast, switching to a new batch with SUFs can occur within one day. This means that a new production run can begin every five days, making facility utilization much higher.
While the consumable costs of disposable fermenter bags, tubing, and filtration equipment recur for each SUF run, they are more than offset by higher throughput and capacity use per annum.
3
No need for cleaning and sterilization between batches
Much of the lag between batches in SS fermenters occurs because the equipment must undergo clean-in-place (CIP) and sterilize-in-place (SIP) before a new batch can be processed. This can take as long as seven days to complete and requires water for injection (WFI) and specialized cleaning chemicals, the supply of which is often constrained.
Cleaning and sterilizing is unnecessary for SUF equipment as it is received as a sterile consumable and is disposable. This reduces the need for CIP chemicals, WFI, and steam for sterilization processing.
SUFs are more automated
Typically, SUFs are provided with a base unit that contains the automation required to perform the process. Support systems can be easily linked to the base units.
SS systems have more complex piping systems and utility connections, making the cost of automation much higher, both for instruments and programming. The fermenter sterile envelope is directly tied to the performance of the automated sequences, therefore increasing the risk of failure if there is any automation issue.
Lower utilities costs
SUFs have lower utility requirements than SS bioreactors. For example, SUFs use one-tenth of the water in the manufacturing process, including WFI and high-purity CIP solutions, significantly reducing daily operating expenses.
Equipment qualification is faster
It takes one-third of the time to qualify SUF equipment compared to SS systems.
Lower risk of cross-contamination
The risk of contamination between batches of one product is significantly reduced, as is the risk when shifting from one product campaign to a different product campaign. This occurs because, not only are the fermenters single use, but their associated components are as well, greatly reducing maintenance‑related batch contaminations.
The risk of contamination between batches of one product is significantly reduced.
Flexibility of production capacity
It is possible to add more production SUFs per batch to increase or control output per cycle. Typically, SUF fermentation suites are designed to accommodate expansion of productivity.
Limitations of SUFs
Despite the many benefits of SUFs, the technology does come with some limitations worth considering.
Culture volume is capped
Compared to the much larger SS bioreactors used for cell culture, the maximum working volume of a SUF is currently capped at 1,000 L, due to conditions unique for microbial cell growth.
Microbes like E. coli are capable of rapid, high-density cell growth, but this requires sufficient agitation and a larger head space in the bioreactor to supply the cells with the oxygen they need. In fermenters, this is measured as the oxygen transfer rate (OTR). In addition, many microbes, such as E. coli and P. pastoris, create excess metabolic heat that must be removed during fermentation.
The ABEC CSR 1,000 L is designed to meet the cooling demands of high‑growth microbial processes and allow an OTR that is similar to what is seen in SS systems of the same volume. However, at volumes greater than 1,000 L, SS bioreactors are still preferred due to the need to maintain aeration, OTR, and provide sufficient cooling at these higher volumes.
Lack of containment against high pressure and flammables
SS fermenters are deliberately over‑pressurized to increase the solubility of oxygen in the culture medium. In addition, P. pastoris may require methanol in its feed stream, adding the further complexity of using a flammable nutrient during fermentation. SS bioreactors have containment protection against overpressure events and fire, while SUFs do not.
The production of recombinant protein therapeutics and reagents
Microbial fermentation at available SUF scales can be used to make small amounts of recombinant protein products in the one-kg range, such as enzyme reagents, highly potent protoxins, or similar high-value, small‑volume products.
Current SUF scales are also ideally suited for rapid and flexible production for clinical trials, with the intention to switch to larger-volume SS fermenters later to produce the amounts required for commercial scale. This would require process modelling to validate that the process performs the same at both scales in the two fermenter types.
Environmental sustainability
Eliminating the need for chemicals and purified water used for CIP as well as the energy required for the extensive SIP of SS vessels shrinks the environmental footprint of single-use fermentation. The microbial culture and other biological waste from the process is treated to kill any organisms, at which point it is no longer hazardous and is safe for discard. The single-use components can be part of a recycling program for the secondary use of plastics once neutralized.
What to look for in a CDMO for microbial fermentation
With faster changeovers, no need for validated cleaning, lower utilities costs, and reduced risk of cross‑contamination, single-use fermenters are a good fit for taking a promising DNA or high‑potency recombinant protein candidate from the lab bench all the way to commercialization.
For those looking to support their next biologics fermentation project, it is important to find a partner that offers the seamless integration of SUF with existing SS systems to expand the scale of production from small-scale clinical amounts all the way to large-scale commercial production.
Additionally, a CDMO partner with a range of microbial fermentation options, combined with process science, solid engineering, cGMP manufacturing, analytical capabilities, and regulatory compliance, all under one company roof, ensures fast delivery, speed to market, and cost efficiency.
Agilent Advanced Therapeutics has a track record of collaborating with our clients to solve the scale-up issues that come from difficult processes.
About us
Agilent Advanced Therapeutics is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.
Flexibility, creativity, process optimization and compliance are at the heart of our method. With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada, we assure our programs advance on time and with high‑quality outcomes.
Figure 1. A 1,000 L fermenter with an operator.
www.agilent.com
RA260105.580
This information is subject to change without notice.
© Agilent Technologies, Inc. 2026
Printed in the USA, September 15, 2026
5994-8919EN
Sponsored by
Download the Whitepaper for FREE Now!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Experiencing issues viewing the form? Click here to access an alternate version